default author photo

Tadaki Suzuki

National Institute of Infectious Diseases - Department of Pathology

Japan

SCHOLARLY PAPERS

5

DOWNLOADS

214

TOTAL CITATIONS

0

Scholarly Papers (5)

1.

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable Site

Number of pages: 52 Posted: 01 Apr 2021
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Center for Research and Education on Drug Discovery, Osaka University - Laboratory of Lymphocyte Differentiation, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Division of Molecular Pathobiology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Kyushu University - Department of Virology, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Virology I, Tottori University - Chromosome Engineering Research Center, Tottori University - Chromosome Engineering Research Center, National Institute of Infectious Diseases - Department of Immunology, Trans Chromosomics Inc., Osaka University - Laboratory of Lymphocyte Differentiation, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology, Hokkaido University - Division of Molecular Pathobiology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 49 (1,074,648)

Abstract:

Loading...

2.

Reduced Resistance of SARS-CoV-2 Variants Toward Affinity-Matured Serological Immunity

Number of pages: 58 Posted: 21 Apr 2021
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Immunology, National Institute of Infectious Diseases - Department of Virology I, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - AIDS Research Center, Tokyo Shinagawa Hospital, Yokohama Municipal Citizen's Hospital - Division of Infectious Disease, Tokyo Medical University, affiliation not provided to SSRN, National Institute of Infectious Diseases, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Department of Bacteriology I, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Pathology and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 43 (1,145,425)

Abstract:

Loading...

3.

Highly Specific Monoclonal Antibodies Against SARS-CoV-2 Nucleocapsid Antigen for Accurate Diagnosis of COVID-19

Number of pages: 33 Posted: 29 Oct 2020
Yokohama City University - Department of Microbiology, Yokohama City University - Department of Microbiology, Yokohama City University - Department of Microbiology, Yokohama City University - Department of Pathology, Yokohama City University - Department of Microbiology, Kanto Chemical Co., Inc. - Life Science Laboratory, Yokohama City Institute of Public Health, Yokohama City Institute of Public Health, Yokohama City Institute of Public Health, Yokohama City University - Department of Microbiology, Yokohama Municipal Citizen's Hospital - Division of Pathology, Yokohama City University - Department of Pathology, Kanto Chemical Co., Inc. - Life Science Laboratory, Kanto Chemical Co., Inc. - Life Science Laboratory, Yokohama Municipal Citizen's Hospital - Division of Infectious Disease, Yokohama City University - Department of Physiology, Yokohama City University - Clinical Laboratory Department, National Institute of Infectious Diseases - Department of Pathology, Gunma Paz University - School of Medical Technology, Faculty of Health Sciences, National Institute of Infectious Diseases - Department of Pathology and Yokohama City University - Department of Microbiology
Downloads 42 (1,157,785)

Abstract:

Loading...

COVID-19, SARS-CoV-2, monoclonal antibody, nucleoprotein, point-of-care testing

4.

High Expression of Polyomavirus-Encoded MicroRNAs in Progressive Multifocal Leukoencephalopathy and BK Polyomavirus-Associated Nephropathy Tissues, and Their Repressive Role in Virus Replication

Number of pages: 29 Posted: 22 Nov 2019
National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology and National Institute of Infectious Diseases - Department of Pathology
Downloads 42 (1,157,785)

Abstract:

Loading...

JC polyomavirus; JCPyV; miRNA; progressive multifocal leukoencephalopathy; in situ hybridisation; polyomavirus

5.

Identification of Anti-COVID-19 Agents, Cepharanthine and Nelfinavir, and Their Potential Usage for Combination Treatment

Number of pages: 36 Posted: 23 Jun 2020
National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, Kyushu University - Department of Biology, National Institute of Advanced Industrial Science and Technology (AIST) - Cellular and Molecular Biotechnology Research Institute, RIKEN Center for Biosystems Dynamics Research - Drug Discovery Structural Biology Platform Unit, Nagahama Institute of Bio-Science and Technology - Department of Bioscience, Nara Institute of Science and Technology - Graduate School of Science and Technology, Kyushu University - Department of Biology, Kyushu University - Department of Biology, Hokkaido University - Center for Research and Education on Drug Discovery, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology I, Indiana University Bloomington - Department of Epidemiology and Biostatistics, National Center for Global Health and Medicine - AIDS Clinical Center, Tokyo University of Science - Faculty of Pharmaceutical Sciences, Tokyo University of Science - Faculty of Pharmaceutical Sciences, Tokyo University of Science - Department of Applied Biological Science, National Institute of Infectious Diseases - Department of Pathology, RIKEN Center for Life Science Technologies - Division of Structural and Synthetic Biology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology I, University of Tokyo - International Research Center for Neurointelligence, Kyushu University - Department of Biology, National Institute of Infectious Diseases - Department of Virology III, University of Oxford - Nuffield Department of Medicine and National Institute of Infectious Diseases - Department of Virology II
Downloads 38 (1,209,354)

Abstract:

Loading...

coronavirus, SARS-CoV-2, COVID-19, antiviral, Nelfinavir, Cepharanthine, protease, spike, in silico